Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Korro Bio (KRRO) Capital Expenditures (2019 - 2025)

Korro Bio's Capital Expenditures history spans 7 years, with the latest figure at $84000.0 for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures fell 94.21% year-over-year to $84000.0, compared with a TTM value of $518000.0 through Dec 2025, down 97.11%, and an annual FY2025 reading of $518000.0, down 97.11% over the prior year.
  • Capital Expenditures for Q4 2025 was $84000.0 at Korro Bio, down from $175000.0 in the prior quarter.
  • The five-year high for Capital Expenditures was $6.0 million in Q2 2024, with the low at -$1.0 million in Q2 2021.
  • Average Capital Expenditures over 5 years is $1.7 million, with a median of $849000.0 recorded in 2023.
  • Year-over-year, Capital Expenditures tumbled 213.53% in 2021 and then skyrocketed 110450.0% in 2023.
  • Tracing KRRO's Capital Expenditures over 5 years: stood at $61000.0 in 2021, then surged by 8319.67% to $5.1 million in 2022, then tumbled by 67.78% to $1.7 million in 2023, then decreased by 12.27% to $1.5 million in 2024, then plummeted by 94.21% to $84000.0 in 2025.
  • Per Business Quant, the three most recent readings for KRRO's Capital Expenditures are $84000.0 (Q4 2025), $175000.0 (Q3 2025), and $140000.0 (Q2 2025).